brand of delavirdine mesylate tablets
RESCRIPTOR Tablets contain delavirdine mesylate, a synthetic non-nucleoside reverse transcriptase inhibitor of the human immunodeficiency virus type 1 (HIV-1).
RESCRIPTOR Tablets are indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted.
The following should be considered before initiating therapy with RESCRIPTOR in treatment-naive patients. There are insufficient data directly comparing RESCRIPTOR-containing antiretroviral regimens with currently preferred 3-drug regimens for initial treatment of HIV. In studies comparing regimens consisting of 2 NRTIs (currently considered suboptimal) to RESCRIPTOR plus 2 NRTIs, the proportion of patients receiving the RESCRIPTOR regimen who achieved and sustained an HIV-1 RNA level <400 copies/mL over one year of therapy was relatively low (see DESCRIPTION OF CLINICAL STUDIES).
Resistant virus emerges rapidly when RESCRIPTOR is administered as monotherapy. Therefore, RESCRIPTOR should always be administered in combination with other antiretroviral agents.
Media Articles Related to Rescriptor (Delavirdine)
Prevention, Treatment Combine to Avert HIV Infection (CME/CE)
Source: MedPage Today Gastroenterology [2015.02.26]
(MedPage Today) -- Complementary interventions drive down risk of transmission in heterosexual couples.
Truvada reduced HIV infection risk by 86% in study
Source: HIV / AIDS News From Medical News Today [2015.02.25]
Researchers have presented findings from a study demonstrating the pre-exposure prophylaxis reduced the risk of HIV infection by 86% among men who have sex with men.
Gel to Prevent HIV Infection Fails -- Again (CME/CE)
Source: MedPage Today OB/Gyn [2015.02.25]
(MedPage Today) -- Poor adherence proves downfall for tenofovir-based treatment.
Exploring common contributors to reducing HIV infections
Source: HIV / AIDS News From Medical News Today [2015.02.06]
Researchers looking for common factors associated with declining HIV infections in four diverse jurisdictions observed that strong leadership within state and local health departments was the most...
amfAR report examines heavy impact of HIV/AIDS on black gay men in the United States
Source: HIV / AIDS News From Medical News Today [2015.02.10]
The nation's inability to effectively address HIV infections among Black gay men is one of the greatest failures of the U.S.
Published Studies Related to Rescriptor (Delavirdine)
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. 
OBJECTIVE: Delavirdine is a non-nucleoside reverse transcriptase inhibitor used in combination regimens for the treatment of HIV-1 infection. Our objective was to characterise the population pharmacokinetics of delavirdine in HIV-infected patients who participated in the adult AIDS Clinical Trials Group (ACTG) 260 and 261 studies... CONCLUSIONS: Delavirdine disposition exhibits nonlinear pharmacokinetics and large interpatient variability, and is significantly altered by time of day (impacting potential therapeutic drug monitoring and future pharmacokinetic study designs). Although race and sex appear to influence delavirdine pharmacokinetics, men and women and patients of different races should receive similar mg/kg dosage regimens. The presence of large interpatient variability supports the further investigation of the utility of therapeutic drug monitoring for delavirdine, if target drug concentrations can be better defined.
Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. [2003.02]
To determine the impact of gastric hypoacidity and acidic beverages on delavirdine mesylate pharmacokinetics in HIV-infected subjects, matched subjects with (n = 11) and without (n = 10) gastric hypoacidity received delavirdine 400 mg tid with either water or an acidic beverage (usually orange juice)...
Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. [2003.01]
AIMS: To evaluate the safety and the pharmacokinetic interaction between amprenavir and delavirdine after multiple dose administration in healthy volunteers... CONCLUSIONS: Amprenavir is an effective inducer of delavirdine metabolism, probably through its effect on hepatic CYP3A4. This could have consequences in other drug-drug interaction situations. Delavirdine is an inhibitor of amprenavir metabolism. The regimen of amprenavir 600 mg and delavirdine 600 mg twice a day is not recommended when an antiretroviral effect from delavirdine is required.
A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. [2001.03]
CONCLUSION: The use of antiretroviral agents that pharmacokinetically boost saquinavir levels has a modest benefit in saquinavir-experienced patients.
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. [2000.11]
We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12.
Clinical Trials Related to Rescriptor (Delavirdine)
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies [Completed]
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate
(Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected
children and babies. This study also examines how the body processes Rescriptor when taken
with 2 NRTIs.
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy [Completed]
To determine the safety and anti-HIV activity of delavirdine mesylate ( U-90152 ) in
combination with zidovudine ( AZT ) and/or didanosine ( ddI ) versus AZT/ddI combination.
U-90152 has demonstrated anti-HIV activity. Since the combination of this drug with either
AZT or ddI has synergistic inhibitory activity against HIV-1 in vitro, and triple therapy
appears to have greater inhibitory activity against HIV-1 in vitro than dual therapy, the use
of U-90152 in combination with AZT and/or ddI may improve the benefits of these drugs in
persons with HIV disease.
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3 [Completed]
To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate
(U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients [Completed]
The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in
combination with two or three other drugs to HIV-infected patients. The drugs to be used in
combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3 [Completed]
PART I: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of three fixed
doses of delavirdine mesylate (DLV) in combination with zidovudine (AZT) versus AZT alone in
PART II: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of ZDV plus 3TC
with or without DLV versus ZDV plus DLV in HIV-positive patients.